The race is on: bispecifics vs CAR T cells in B-cell lymphoma

This is the authors' abstract. We don't add key points for this paper.

T-cell therapeutic approaches have come of age over the last 5 years and dramatically changed the treatment paradigm for relapsed/refractory (R/R) indolent and aggressive B-cell lymphomas.This consists of bispecific T-cell engaging antibodies (BiAbs) and autologous, ex vivo, expanded T cells with a chimeric antigen receptor (CAR T).Both of these therapies result in target cell lysis independent of T-cell receptor specificity and major histocompatibility complex presentation of a tumor antigen. 1 BiAbs combine the antigen binding regions from 2 different single chain antigen binding domains to form an antibody construct binding, with one arm to a surface antigen on B cells, for example CD20, and the second arm to an activating component of the T-cell receptor, CD3, causing cytotoxic T-cell activation and lysis.